Page 1 of 27



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
----------------------------------
FORM 10-K

[X]  ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
      SECURITIES EXCHANGE ACT OF 1934

     For the Fiscal Year Ended June 30, 1998

OR

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES EXCHANGE ACT OF 1934

      Commission File Number  0-11250

                          DIONEX CORPORATION					
            (Exact name of registrant as specified in its charter)

            Delaware		             	   94-2647429		
(State or other jurisdiction of			(I.R.S. Employer 
 incorporation or organization)			Identification No.)
                                                                      
1228 Titan Way, Sunnyvale, California		     94086		
(Address of principal executive offices)	   (Zip Code)

Registrant's telephone number, including area code (408) 737-0700

Securities registered pursuant to Section 12(b) of the Act:   None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $.001 per share

Indicate by check mark whether the registrant (1) has filed all 
reports required to be filed by Section 13 or 15(d) of the 
Securities Exchange Act of 1934 during the preceding 12 months (or 
for such shorter period that the registrant was required to file 
such reports), and (2) has been subject to such filing 
requirements for the past 90 days. 	YES  X	   NO_____

Indicate by check mark if disclosure of delinquent filers pursuant 
to Item 405 of Regulation S-K is not contained herein and will not 
be contained, to the best of registrant's knowledge, in definitive 
proxy or information statements incorporated by reference in Part 
III of this Form 10-K or any amendment to this Form 10-K.  [X]

The aggregate market value of the Registrant's Common Stock held 
by nonaffiliates on September 23, 1998 (based upon the closing 
price of such stock as of such date) was $522,351,716.

As of September 23, 1998, 22,210,656 shares of the Registrant's 
Common Stock were outstanding.

Portions of the Registrant's 1998 Annual Report to Stockholders 
are incorporated by reference in Parts I, II and IV of this 
Report.  Portions of the Registrant's definitive Proxy Statement 
for the Annual Meeting of Stockholders to be held on October 22, 
1998 are incorporated by reference in Part III of this Report. 












































2
<PAGE>
PART I

Item 1.  BUSINESS 

	   Dionex Corporation* designs, manufactures, markets and 
services analytical instrumentation and related accessories and 
chemicals.  The Company's products are used to analyze chemical 
substances in the environment and in a broad range of industrial 
and scientific applications.  Since July 1, 1997, there have been 
no material changes in the mode of conducting the business of the 
Company.

	   Industry Segment Information

	   The Company operates in a single industry segment 
consisting of analytical instruments and related services.

	   Products

	   Dionex develops, manufactures, markets and services a 
range of chromatography systems, sample preparation devices and 
related products that are used by chemists to separate and 
quantify the individual components of complex chemical mixtures in 
many major industrial, research and laboratory markets.  
Typically, the Company's chromatography systems consist of several 
components including a specially designed liquid pumping and flow 
system, a sample injection system, a separator column, a 
suppressor or other post-column device, a detector and a data 
collection and analysis system.  These components are designed to 
be modular so that systems can be configured to meet the 
particular analytical requirements of individual customers.  
Moreover, individual components may be sold separately to existing 
customers that wish to expand their systems.

	   The Company's chromatography systems are currently focused 
in several product areas: ion chromatography (IC), high 
performance liquid chromatography (HPLC) and sample extraction.  
In addition to these product areas, the Company develops and 
manufactures columns, detectors, data analysis systems and other 
products.  Each of these product areas is described below.

Ion Chromatography and HPLC - Ion Chromatography is a form of 
chromatography that separates ionic (charged) molecules, usually 
found in water-based solutions, and typically separates and 
detects them based on their electrical conductivity.  The sale of 
Dionex IC systems and related columns, suppressors, detectors, 
automation and other products accounts for a majority of the 
Company's revenues.
     _________________________
     *	Unless the context otherwise requires, the terms
		"Dionex" and "the Company" as used herein include
		Dionex Corporation, a Delaware corporation, and its
		subsidiaries.  Dionex was initially incorporated
		in California in 1980.  In 1986, the Company
		reincorporated in Delaware.

3
<PAGE>
	  Dionex IC products are used in a wide range of 
applications, including environmental monitoring, corrosion 
monitoring, evaluation of raw materials, quality control of 
industrial processes, quality control of pharmaceutical and 
industrial products, research and development, and regulation of 
the chemical composition of food, beverage and cosmetic products.  
Major customers include environmental testing laboratories, life 
science and food companies, chemical and petrochemical firms, 
power generating facilities, electronics manufacturers, government 
agencies and academic institutions.

HPLC is a form of chromatography that separates molecules such as 
proteins, carbohydrates, amino acids, pharmaceuticals and 
chemicals and identifies them by measuring the amount of light 
that the molecules absorb or emit when exposed to a light source.  
The Company's customers include biological research and 
biotechnology groups, pharmaceutical and other industrial 
companies.

	  In fiscal 1994, the Company introduced the DX-500 Series of 
chromatography systems for IC and HPLC in the North American and 
European markets.  In fiscal 1995, the DX-500 line was introduced 
in Japan and is now marketed worldwide.  The modular, high 
performance system offers various configurations designed to meet 
the needs of numerous IC and HPLC applications.  The DX-500 Series 
offers both quaternary gradient and isocratic pump capabilities, 
in either PEEK (polyetheretherketone) or stainless steel and 
several detection modes based on conductivity, electrochemistry 
and optical absorbance.  This versatility of detection and pumping 
capabilities allows customers to perform a wide range of IC and 
HPLC applications. In March 1997, the Company introduced the LC25 
oven, an oven that features both conductive and convective heating 
to facilitate temperature control of columns, cells and 
suppressors.  In April 1998,the Company enhanced the DX-500 
product line by introducing the GP50 and IP25 pumps.  These pumps 
are the second generation of pumps in the DX-500 product line and 
are designed to provide more reliable flow and gradient accuracy 
and precision.  In March 1998, the Company introduced the EG40 
Eluent Generator, a module for use with the DX-500 system.  The 
EG40 generates high-purity eluents on-line using only deionized 
water as the carrier.  The benefits of the on-line eluent 
generation is improved results by eliminating interferences, 
enhancing sensitivity and providing greater flexibility.  

	  In fiscal 1996, the Company introduced the DX-120, a
cost-effective IC system for customers that need simple, dedicated 
instrumentation for routine ion analysis.  The DX-120 was designed 
for improved reliability and automation, allowing for quick
set-up, simple operation and high quality isocratic performance.  
The DX-120 is marketed worldwide.






4
<PAGE>
	  In fiscal 1998, the Company began shipping the DX-800, the 
next generation continuous on-line monitoring system.  The DX-800 
uses industry standard PC-based automation, similar to that used 
in laboratory chromatography.  Major applications for the 
Company's DX-800 are in the power industry for the continuous 
monitoring of corrosive contaminants in boiler water, the 
semiconductor industry for continuous monitoring of contaminants 
in high purity water and continuous monitoring of biological and 
chemical synthesis processes.  The DX-800 is marketed worldwide.

Sample Extraction  - The Company offers the ASETM 200 system for
automated sample extraction.  In fiscal 1995, the Company 
introduced this new extraction technology called Accelerated 
Solvent Extraction or ASE.  The ASE 200 system extracts solid 
samples using common solvents at elevated temperatures and 
pressures.  The ASE 200 system extracts solid samples in an 
automated fashion using the same solvents used in traditional 
soxhlet techniques. Competitive techniques include soxhlet, 
sonication, microwave extraction and supercritical fluid 
extraction.  The ASE 200 system offers several advantages over 
other solvent based extraction techniques including lower solvent 
consumption, reduced extraction time, higher throughput through 
automation and ease of use.  ASE 200 systems are used worldwide 
for a number of environmental, industrial and food and beverage 
applications.  In March 1997, the Company enhanced its ASE 200 
system by introducing the ASE 200 Solvent Controller Module, which 
automates the delivery of multiple solvents to the ASE 200 system, 
and Auto ASE, an add-on software feature which allows control of 
up to eight ASE 200 systems from one location, as well as methods 
storage and documentation.

Automation Products - As part of its efforts to make chemical 
analyses simpler, faster and more reliable, Dionex offers a family 
of products that automate sample handling, system operation and 
data analysis for chromatography systems.  These products include 
the PeakNet and PeakNet PA for Process Analysis.  In addition, 
automated sample injectors are available.

	  In fiscal 1994, the PeakNet PC-based Chromatography 
Workstation was introduced.  PeakNet is the Company's latest 
release of Windows-based applications for chromatography.  PeakNet 
Workstations are multi-featured, high performance computer systems 
that automate control, data acquisition, analysis and reporting 
for the DX-120, DX-500 and DX-800 systems.  In fiscal 1996, the 
Company introduced PeakNet 4.3, which offered new capabilities 
including data smoothing options to reduce noise and enhanced 
reporting formats to meet the changing documentation requirements 
of our customers.  In fiscal 1997, the Company introduced its 
latest version of the software, PeakNet 5.0, a new generation 32-
bit automation product designed for use with Windows 95 and 
Windows NT.  In March 1998, the Company enhanced its PeakNet 
chromatography software by introducing PeakNet 5.1.  This release 
added new capabilities to the PeakNet software, including full 
control and support of the EG40 and enhanced reporting 
capabilities.

5
<PAGE>
	  In fiscal 1994, the universal interface (UI20) module was 
added to PeakNet.  It allows PeakNet workstations to accept data 
from other Dionex instruments, as well as instruments manufactured 
by other vendors.  A revision of the PeakNet software was also 
introduced at that time to support the new interfacing 
capabilities.

	  Also in fiscal 1994, a new Automated Sample Injection 
module (AS40) was introduced.  The AS40 can be used with the DX-
120 and DX-500 series.                 

Columns and Suppressors - A chromatography column generally
consists of a hollow cylinder packed under high pressure with a 
chemical resin.  The column's function is to separate various 
chemical components in a sample.  The Company develops and 
manufactures its own resins using proprietary processes.  Dionex 
currently manufactures and markets a broad range of column types 
designed for particular applications in the liquid chromatography 
market.

	Several consumable products were introduced in fiscal 1998, 
including the IonPac AS11-HC for determination of organic and 
inorganic acid anions in diverse matrices and the IonPac AS15 for  
determination of trace level concentrations of a wide variety of 
inorganic anions and low molecular weight organic acids in the 
power and semiconductor markets.  In addition, the Company 
introduced the IonPac ICE-Borate and Trace Borate Concentrator 
columns for determination of borate at low parts-per-trillion 
concentrations in ultra high-purity water samples.
	
	These products follow a steady stream of columns and 
chemistries introduced in the previous two years, including the 
IonPac AS9-HC, IonPac CS15, IonPac AS14, IonPac CS5A and CarboPac 
PA10.  These products cover a range of applications.

	In addition to columns, Dionex manufactures suppressors that 
are used to enhance detection in ion chromatography.  The Company 
has proprietary positions in the technology of suppression used in 
ion chromatography as well as in the application of suppression 
techniques.  The Company's suppressors lower background 
conductivity while allowing separations using higher capacity 
columns and more concentrated eluents (liquids used to carry a 
sample through a liquid chromatography system).  In fiscal 1993, 
Dionex enhanced its suppression technology with the introduction 
of a new AutoSuppression product.  The product, called the Self-
Regenerating Suppressor (SRSTM), enhances IC performance while 
operating with low maintenance requirements.  In fiscal 1997, the 
Company introduced the SRS-II, designed to allow use with a wide 
range of solvents at various temperatures.

In March 1998, the Company introduced the SRS-Ultra, the next 
generation in the SRS line of suppressors.  The SRS-Ultra provides 
superior performance for trace level ion chromatography.




6
<PAGE>
Detectors - Detectors are used to measure the quantity of various 
sample components after they have been separated in a 
chromatography column.  Dionex currently offers several detector 
products based on conductivity, electrochemistry and absorbance, 
including a photodiode array detector introduced in 1995.  This 
range of detectors is designed to meet customer requirements for 
analysis of organics, inorganics, metals, amino acids, biological 
compounds and pharmaceuticals.

Service and Other -  The Company also generates revenue from its 
Customer Service organization through service contracts, spare 
part sales, customer training and sales of other products and 
services.  (See Technical Support, Installation and Service 
below.)

Marketing and Customers

	The Company's market strategy is twofold.  First, in those 
applications where Dionex technology is well established, the 
Company works to increase demand for its chromatography systems 
through direct mailings, advertising in trade publications, 
seminars and workshops, conferences and expositions, and direct 
sales calls.  Growth in these markets results from identifying new 
customers in existing sales regions, extending geographic 
penetration and increasing demand for the Company's products and 
technical support capabilities among existing customers.

	The second component of the Company's marketing strategy is 
to work closely with existing and potential customers to develop 
new applications.  Technical support staff assist such customers 
in problem definition, development of new applications needed to 
solve problems and providing user training and ongoing user 
support.  By combining this support function with direct sales 
efforts, the Company works to increase the range of applications 
and the potential market for its products.

	The Company currently markets and distributes its products 
and services through its own sales force in the United Kingdom, 
Germany, Italy, France, the Netherlands, Belgium, Switzerland, 
Austria, Japan, Canada and the United States.  In each of these 
countries, the Company maintains one or more local sales offices 
in order to service customers in regional markets.  In other 
international locations where it does not have a direct sales 
force, the Company has developed a network of distributors and 
sales agents.

	The Company's products are used extensively in environmental 
analysis and by the pharmaceutical, life science, biotechnology, 
chemical, petrochemical, power generation, food and beverage and 
electronics industries.  Its customers include a number of the 
largest industrial companies worldwide, as well as government 
agencies, research institutions and universities.  Geographically, 
sales to customers outside of North America accounted for 57% of 
consolidated sales in fiscal 1998 and 61% of consolidated sales in 
both fiscal 1997 and fiscal 1996.  No single customer accounted 
for 10% or more of the Company's sales in fiscal 1998, 1997 or 
1996.
7
<PAGE>
	Demand for the Company's products is dependent upon the size 
of the markets for its chromatography systems, the level of 
capital expenditures of the Company's customers, the rate of
economic growth in the Company's major markets and competitive 
considerations.  There can be no assurances that the Company's 
results of operations will not be adversely impacted by a change 
in any of the factors listed above.  The Company believes that 
demand for its products does not exhibit any significant seasonal 
pattern.

	Dionex manufactures its products based upon its forecast of 
customer demand and maintains inventories of completed modules in 
advance of receipt of firm orders from its customers.  Orders are 
generally placed by the customer on an as-needed basis, and 
products are usually shipped within four to six weeks after 
receipt of an order.  Dionex does not maintain a substantial 
backlog, and backlog as of any particular date may not be 
indicative of the Company's actual sales in any succeeding period.  
The level of backlog at June 30, 1998 was $18.4 million and at 
June 30, 1997 was $19.0 million.

	Competition

	Competition in the Company's business segment is based upon 
the performance capabilities of the analytical instrument, 
technical support and after-market service, the manufacturer's 
reputation as a technological leader and the selling price.  
Management believes that performance capabilities are the most 
important of these criteria.  Customers measure system performance 
in terms of sensitivity (the ability to discern minute quantities 
of a particular sample component), selectivity (the ability to 
distinguish between similar components), speed of analysis and the 
breadth of samples that the system can effectively analyze.  
Management believes that Dionex enjoys a favorable reputation in 
terms of performance capabilities, technical support and service.

	Companies competing with Dionex in the analytical instruments 
market include Hewlett-Packard Company, Perkin-Elmer Company, 
Varian Associates, Inc., Shimadzu Corporation, Thermo Instruments 
and Waters Corporation. The Company believes no single competitor 
has a dominant position in the analytical instruments market.  The 
Company believes it has a major position in IC, one of many 
different analytical techniques.  Competitors of the Company in IC 
include HPLC vendors such as Hewlett-Packard Company, Waters 
Corporation, Alltech Associates, Lachat and other smaller 
companies. 











8
<PAGE>
	Dionex IC systems generally compete with a number of 
analytical techniques used in identifying and quantifying ionic 
and polar compounds.  The two primary sources of competition for 
ion chromatography are conventional manual and automated wet 
chemistry procedures and certain modified liquid chromatography 
systems.  Some suppliers of liquid chromatography systems have 
developed a single column ion chromatography (SCIC) method that 
does not use a suppressor device.  SCIC methods compete favorably 
with Dionex ion chromatography for the analysis of a limited 
number of ions and in situations when chemical composition of the 
sample is not complex or when high sensitivity is not required.  
The introduction in 1993 by the Company of AutoSuppression 
technology considerably improves the ease of use of chemical 
suppression.  In addition to SCIC products, the Company's 
competitors also offer other products to compete in ion analysis 
and chromatography products using technology similar to that 
offered by the Company in earlier generation modules during the 
1980's.  

	The Company's DX-500 Series competes directly with other 
manufacturers' HPLC systems in certain traditional HPLC 
applications.  Dionex is a relatively new entrant in the highly 
competitive HPLC and biological separations markets. Nonetheless, 
management believes that the DX-500 Series has certain benefits 
over competing systems, including a non-metallic flow path and the 
capability of performing gradient ion chromatography, as well as 
HPLC, on a single analytical system.

	The Company's ASE 200 competes directly with standard 
soxhlet, sonication, supercritical fluid extraction and microwave 
extraction techniques provided by other companies.  Management 
believes that the ASE 200, has certain benefits compared to 
competing techniques, including faster extraction time, reduced 
solvent usage and built-in automation.

	The Company believes that competition in the ion analysis 
market will continue to increase in the future.  Moreover, the 
Company's entrance into the HPLC and sample extraction markets has 
resulted in increased competition. Many of the companies whose 
products compete with those of the Company have substantially 
greater financial resources and larger technical staffs and sales 
forces at their disposal.  There can be no assurances that the 
Company's marketing and sales efforts will compete successfully 
against such other companies in the future.













9
<PAGE>
	Patents and Licenses

	The Company has an extensive patent portfolio, including 
exclusive licenses to patents from the Dow Chemical Company 
("Dow") (except for rights retained by Dow and its subsidiaries) 
covering certain of the Company's products.  The primary benefits 
of patents are presently limited to the United States and certain 
other foreign countries where patents have been issued.  With 
regard to the Dow licenses,Dow and its subsidiaries reserve the 
right to practice the patents, and Dow has made products covered 
by the patent rights for its own use.  The Company believes that 
Dow has not made products covered by the patent rights for sale to 
third parties.

	As a matter of Company policy, the Company vigorously 
protects its intellectual property rights and seeks patent 
coverage on all developments that it regards as material and 
patentable.  However, there can be no assurances that any patents 
held by the Company will not be challenged, invalidated or 
circumvented or that the rights granted thereunder will provide 
competitive advantages to the Company.  The Company's patents, 
including those licensed from others, expire on various dates 
through 2011.  The Company believes that, while its patent 
portfolio has value, no single patent or patent application is in 
itself essential and that the invalidity or expiration of any 
single patent would not have a material adverse effect on its 
business.

	The Company regards its PeakNet software as proprietary and 
relies on a combination of copyrights, trademarks, trade secret 
laws and other proprietary rights, laws, license agreements and 
other restrictions on disclosure, copying and transferring title 
to protect its rights to its software products.  The Company has 
no patents covering its software, and existing copyright laws 
afford only limited practical protection.  In addition, the laws 
of some foreign countries do not protect the Company's proprietary 
rights to the same extent as do the laws of the United States.

	International Operations

	Financial information about foreign and domestic operations 
and export sales required by Item 1 of Form 10-K is incorporated
by reference to Note 11 of the Notes to Consolidated Financial 
Statements at page 37 of the Registrant's 1998 Annual Report to 
Stockholders.  A copy of the applicable page is included as 
Exhibit 13.1.











10
<PAGE>
	The Company has subsidiaries in the United Kingdom, Germany, 
Italy, France, the Netherlands, Belgium, Switzerland, Austria, 
Japan and Canada. The Company's foreign sales are affected by 
fluctuations in currency exchange rates and by regulations adopted 
by foreign governments.  Export sales are subject to certain 
controls and restrictions, but the Company has not experienced any 
material difficulties related to these limitations.  There can be 
no assurances that the Company's results of operation will not be 
adversely impacted by fluctuations in currency exchange rates in 
the future.

	Manufacturing and Suppliers

	The Company produces chemicals and resins and assembles 
systems and components in its California manufacturing facilities.  
Dionex has developed proprietary processes for the manufacture of 
polystyrene-based resins and for packing columns with these 
resins.  The Company believes that its resins, columns and 
suppressor manufacturing know-how are critical to the performance 
and reliability of its chromatography systems.  The Company 
requires each employee to sign a nondisclosure agreement to 
protect its proprietary processes.  However, there can be no 
assurances that these agreements will provide meaningful 
protection or adequate remedies for the Company's proprietary 
processes in the event of unauthorized use or disclosure.

	The Company has emphasized a modular design for the principal 
subsystems of its pumping flow systems, sample injection systems, 
chromatography modules, detectors, and control and data analysis 
systems.  The Company believes that this modular approach has 
enabled it to meet the wide range of system configurations 
required by its customers while effectively managing inventory 
levels.

	Many components used in the Company's products, including 
proprietary analog and digital circuitry, are manufactured by 
Dionex.  Other components, including packaging materials, 
integrated circuits, microprocessors, microcomputers and certain 
detector and data analysis modules, are acquired from other 
manufacturers.  Most of the raw materials, components and supplies 
purchased by the Company are available from a number of different 
suppliers; however, a number of items are purchased from limited 
or single sources of supply, and disruption of these sources could 
have a temporary adverse effect on shipments and the financial 
results of the Company.  The Company believes alternative sources 
could ordinarily be obtained to supply these materials, but a 
prolonged inability to obtain certain materials or components 
could have an adverse effect on the Company's financial condition 
or results of operations and could result in damage to its 
relationship with its customers.  







11
<PAGE>
	Technical Support, Installation and Service

	Users of the Company's chromatography systems require 
substantial technical support before and after the system sale to 
ensure that analysis problems are resolved.  As part of its 
support services, the Company's technical support staff provides, 
typically at no additional cost, individual assistance in solving 
chemical analysis problems.  The Company offers training courses 
and periodically sends its customers information on applications 
development. Chromatography systems sold by the Company generally 
include a one-year warranty, installation and certain user 
training, all at no additional cost.  Service contracts may be 
purchased by customers to cover equipment no longer under 
warranty.  Service work not performed under warranty or service 
contracts is performed on a time and materials basis.  The Company 
installs and services its products through its own field service 
organization in the United Kingdom, Germany, Italy, France, the 
Netherlands, Belgium, Switzerland, Austria, Japan, Canada and the 
United States.  Installation and service in other foreign 
countries are typically provided by the Company's distributors or 
agents.

	Research and Development

	The Company's research and development efforts are focused on 
increasing the performance of its chromatography and other 
products and expanding the number of chemical compounds that can 
be analyzed efficiently with its products.  Research and product 
development expenditures were $13.3 million, $12.5 million and 
$11.5 million in fiscal 1998, 1997 and 1996, respectively.  The 
Company pursues active development programs in the areas of system 
hardware, applications, computer software, suppressors, resin and 
column technologies.  There can be no assurances that the 
Company's product development efforts will be successful or that 
the products developed will be accepted by the marketplace.

	Environmental Laws and Regulations

	Compliance by the Company with federal, state and local 
environmental laws during fiscal 1998 had no material effect upon 
capital expenditures, earnings or its competitive position.

	Employees

	Dionex had 715 employees at June 30, 1998, compared with 685
employees at June 30, 1997.  The Company believes that its future 
success depends in large part upon its continued ability to 
attract and retain highly skilled employees.  









12
<PAGE>
Item 2.   PROPERTIES

		As of September 23, 1998 the Company owned nine
		buildings in Sunnyvale, California, providing 252,000
		square feet of space utilized for Administration,
		Marketing, Sales, Service, Research and Product
		Development and Manufacturing.  The Company also owns
		a building utilized for Sales, Service and
		Administration in Idstein, Germany.  

		The Company leases sales and service offices in:
		Atlanta, Georgia; Houston, Texas; Westmont, Illinois;
		Marlton, New Jersey; Sunnyvale, California; and in the
		United Kingdom, Germany, France, Italy, the
		Netherlands, Belgium, Switzerland, Austria, Japan and
		Canada.  In addition, the Company leases marketing and
		research and development offices in Salt Lake City,
		Utah.  

		The Company's facilities are well maintained, adequate
		to conduct the Company's current business and
		substantially utilized by the Company.  

		Several of the Company's properties are located in an
		area under investigation by the California Regional
		Water Quality Control Board (the "Water Board".)  The
		Water Board's investigation addresses the presence of
		certain volatile organic compounds in portions of the
		local groundwater system and focuses principally on the
		activities of several other companies located near the
		Company.  The Water Board review has encompassed the
		property acquired by the Company in July 1986.  The
		Company believes that any remedial work affecting
		the subject property will be performed by or at the
		expense of other parties responsible for any release of
		chemicals onto the property, or at the expense of the
		previous owner of the property.  As a result,
		management believes that any action required by the
		Water Board's investigation will not have a material
		adverse effect on the Company's financial position or
		results of operations.


Item 3.  LEGAL PROCEEDINGS

	    None.











13
<PAGE>
Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

	    No matters were submitted to a vote of security holders
	    during the quarter ended June 30, 1998.


	Executive Officers of the Registrant

	The following table lists the names and positions of all 
current executive officers of the Company, and their ages as of 
September 18, 1998.  Except as noted below, there are no other 
family relationships between any director or executive officer and 
any other director or executive officer of the Registrant.  
Executive officers serve at the discretion of the Board of 
Directors.

          Name		          Age              Positions

	A. Blaine Bowman(1)	     	52		President, Chief Executive
                       								Officer and Director

	Barton Evans, Jr.        	50		Senior Vice President

	Nebojsa Avdalovic	       	63		Vice President

	Bruce L. Barton	         	39		Vice President

	Brent J. Middleton(1)    	41		Vice President

	Christopher Pohl	        	47     	Vice President

	Michael W. Pope	         	32		Vice President

	(1) Mr. Bowman and Mr. Middleton are cousins.

	Mr. Bowman has served as the Registrant's President and Chief 
Executive Officer and as a director since the Registrant began 
operations in 1980. Mr. Bowman is also a director of Molecular 
Devices Corporation.  

Mr. Evans has served as Senior Vice President, Operations for 
the Registrant since September 1993.  Prior to that, he served as 
Vice President, Operations and in various other capacities for the 
Registrant since it began operations in 1980.  

Dr. Avdalovic has served as Vice President, Research and 
Development for the Registrant since August 1990.  Prior to 
joining the Registrant, Dr. Avdalovic served as Research Manager 
and Manager of Technology Assessment for Beckman Instruments 
Spinco Division in Palo Alto, California.







14
<PAGE>
Mr. Barton has served as Vice President, International
Operations for the Registrant since July 1996.  Prior to that, he 
served as Director of International Operations and in various 
other capacities since joining the Company in 1987.

Mr. Middleton has served as Vice President, North American 
Sales and Service since July 1997.  Prior to that, he served as 
Director of North American Sales and Service and in various other 
capacities since joining the Company in 1985.

	Mr. Pohl has served as Vice President, Consumables for the 
Registrant since September 1996.  Prior to that, he served as
Technical Director and in various other capacities for the 
Registrant since the Company began operations in 1980.

	Mr. Pope has served as Vice President, Finance and 
Administration for the Registrant since April 1995.  Prior to 
that, he served as Director of Finance and Senior Financial 
Analyst with the Company.  Mr. Pope has been with the Company 
since June 1992.  


PART II


Item 5.  MARKET FOR REGISTRANT'S COMMON STOCK AND RELATED
	    STOCKHOLDER MATTERS

	    The information required by Item 5 of Form 10-K is
	    incorporated by reference to the information contained
	    in the section captioned "Supplemental Information" at
	    page 40 of the Registrant's 1998 Annual Report to
	    Stockholders.  A copy of the applicable page is attached
	    hereto as Exhibit 13.1.

Item 6.  SELECTED CONSOLIDATED FINANCIAL DATA

	    The information required by Item 6 of Form 10-K is
	    incorporated by reference to the information contained
	    in the section captioned "Selected Financial
	    Information" at page 24 of the Registrant's 1998 Annual
	    Report to Stockholders.  A copy of the applicable page
	    is attached hereto as Exhibit 13.1.  














15
<PAGE>
Item 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
         CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

The following table summarizes the consolidated income statement 
items as a percentage of sales.

PERCENTAGE OF NET SALES

Years ended June 30			            		1998	    	1997	     	1996	 

Net sales						                    100.0%    100.0%     100.0%
Cost of sales					                  31.5	     30.6	      31.1
Gross profit					                   68.5	     69.4	      68.9
Selling, general and administrative 31.7      33.3	      34.8
Research and product development	    8.8       8.8	       8.7
Operating income				                28.0	     27.3	      25.4
Other income					                    -	        - 	        0.8
Interest income, net			               .8	       .9	       1.4
Income before taxes				             28.8	     28.2	      27.6
Taxes on income				                  9.8	      9.7	       9.6
Net income					                     19.0%    	18.5%	     18.0%


NET SALES AND GROSS PROFIT.  In fiscal 1998, Dionex reported 
record sales and earnings for the 18th consecutive year. The 
Company's consolidated sales in fiscal 1998 were $150.5 million, 
an increase of 6% compared with $142.1 million in fiscal 1997. 
Sales in fiscal 1996 were $133.0 million. The Company is subject 
to the effects of foreign currency fluctuations, which can have an 
impact on reported sales and gross profits. Currency fluctuations 
reduced reported sales by 4% in both fiscal 1998 and fiscal 1997. 
Sales growth in fiscal 1998 was fueled by strong growth in North 
America and Europe in local currencies. However, a strengthening 
U.S. dollar reduced the results in Europe. Sales in the Far East 
declined slightly due to the Asian financial crisis and a stronger 
U.S. dollar. Sales growth in fiscal 1997 was split evenly between 
our North American and international markets, with solid growth in 
the Far East offset by some weakness in certain of our European 
markets. The Company anticipates that the financial crisis in Asia 
will continue to have an unfavorable impact on sales growth for 
the near future.

Sales outside of North America accounted for 57% of consolidated 
sales in fiscal 1998 and 61% of consolidated sales in fiscal 1997 
and fiscal 1996. The Company sells directly through its sales 
forces in the United Kingdom, Germany, Italy, France, the 
Netherlands, Belgium, Switzerland, Austria, Japan, Canada and the 
United States. Direct sales accounted for 90% of consolidated 
sales in fiscal 1998, compared to 88% in fiscal 1997 and 89% in 
fiscal 1996. International distributors and representatives in 
Europe, the Far East and other international markets accounted for 
the balance of consolidated sales. There were no significant price 
changes during the three-year period.


16
<PAGE>
Gross profit as a percentage of consolidated sales was 68.5% in 
fiscal 1998, compared with 69.4% in fiscal 1997 and 68.9% in 
fiscal 1996. The decrease in gross profit in fiscal 1998 was 
attributable to a stronger U.S. dollar. The increase in gross 
profit in fiscal 1997 was attributable to increased sales of 
higher-margin products and lower manufacturing costs, partially 
offset by the negative effect of currency fluctuations.

OPERATING EXPENSES.  Selling, general and administrative ("SG&A") 
expenses as a percentage of net sales decreased to 31.7% in fiscal 
1998, compared with 33.3% in fiscal 1997 and 34.8% in fiscal 1996. 
SG&A expenses increased 1% in fiscal 1998 to $47.7 million 
compared with $47.3 million in fiscal 1997, due to higher 
personnel and related costs, partially offset by the effect of 
currency fluctuations.

Fiscal 1997 SG&A expenses increased 2% to $47.3 million compared 
with $46.3 million in fiscal 1996. The increase was due to the 
establishment of a new direct sales subsidiary in Austria in 
January 1997, increased selling costs and higher personnel-related 
costs, partially offset by the effect of currency fluctuations. 
The Company anticipates that SG&A expenses will be in the range of 
31% to 34% of sales in the near term. Research and product 
development expenses were 8.8% of consolidated sales in fiscal 
1998, unchanged from fiscal 1997, and slightly higher than the 
8.7% reported in fiscal 1996. Research and product development 
expenses in fiscal 1998 were $13.3 million, an increase of 6% 
compared with $12.5 million in fiscal 1997. The increase was due 
to higher personnel and related costs and higher project material 
costs associated with various product development projects. 
Research and product development expenses in fiscal 1997 increased 
9% from the $11.5 million reported in fiscal 1996. Research and 
product development spending depends on both the breadth of the 
Company's research and product development efforts and the stage 
of specific product development projects. The Company expects the 
level of research and product development expense to remain in the 
range of 8% to 10% of sales in the near term.

OTHER INCOME.  Other income in fiscal 1996 included a gain of $1.0 
million on the sale of undeveloped property. Proceeds (net of 
selling expenses) from the sale of the property were $3.9 million. 
The proceeds consisted of cash and the assumption by the buyer of 
an industrial revenue bond associated with the property. 














17
<PAGE>
INTEREST INCOME.  Interest income in fiscal 1998 of $1.4 million 
was essentially unchanged from fiscal 1997.  Fiscal 1997 interest 
income was 31% lower than the $2.0 million reported in fiscal 
1996. Lower average invested cash balances in 1998 were offset by 
higher yields on investments. Fiscal 1997 was lower than fiscal 
1996 due to lower average cash balances. Lower average cash 
balances in fiscal 1998 and 1997 resulted from the purchase of the 
Company's stock under its stock repurchase program.

INCOME TAXES.  The Company's effective tax rate for fiscal 1998 
was 34.0%, compared with 34.5% in fiscal 1997 and 34.8% in fiscal 
1996.  The Company's effective tax rate is affected by the mix of 
taxable income among the various tax jurisdictions in which the 
Company does business. The Company anticipates that its effective 
tax rate will be in the 33% to 35% range in the near term.

EARNINGS PER SHARE.  Diluted earnings per share in fiscal 1998 
increased 15%, to $1.18 per share, compared with $1.03 in fiscal 
1997 and $.87 in fiscal 1996. Fiscal 1996 includes $.02 per share 
resulting from a gain on the sale of property. Basic earnings per 
share in fiscal 1998 increased to $1.25, compared with $1.09 in 
fiscal 1997 and $.91 in fiscal 1996. The number of shares used in 
computing diluted and basic earnings per share declined each year 
due to the Company's stock repurchase program. On December 29, 
1995 and June 5, 1998, the Company effected two-for-one splits of 
its common stock. All per-share and share amounts have been 
restated to reflect the stock splits.

LIQUIDITY AND CAPITAL RESOURCES.

In fiscal 1998, the Company maintained its strong liquidity and 
financial condition. The Company's working capital was $35.7 
million at June 30, 1998. Working capital decreased in fiscal 
1998, because the Company repurchased 1,851,460 shares of its 
common stock for $46.2 million under its stock repurchase program. 
The Company repurchased 1,583,478 shares for $31.0 million in 
fiscal 1997 and 3,202,000 shares for $49.1 million in fiscal 1996. 
Cash generated by operating activities was $27.9 million, compared 
with $27.0 million in fiscal 1997 and $27.7 million in fiscal 
1996. The increase in operating cash flows was due to higher net 
income, partially offset by higher accounts receivable. Capital 
expenditures in fiscal 1998 decreased to $2.5 million, compared 
with $2.6 million in fiscal 1997 and $3.0 million in fiscal 1996. 
The higher level in fiscal 1996 was due to the renovation of a 
manufacturing building. At June 30, 1998, the Company had no 
borrowings outstanding under any of its $14.1 million bank lines 
of credit, which are used to meet working capital requirements and 
reduce exposure to foreign currency fluctuations. The Company 
believes that its cash flow from operations, its current cash and 
cash investments and its bank lines of credit are sufficient to 
meet its cash requirements for the foreseeable future. The impact 
of inflation on the Company's financial position and results of 
operations was not significant during any of the periods 
presented.



18
<PAGE>
New accounting pronouncements.  In June, 1997, the Financial 
Accounting Standards Board issued Statement of Financial 
Accounting Standards (SFAS) No. 130, "Reporting Comprehensive 
Income," and Statement of Financial Accounting Standards (SFAS) 
No. 131, "Disclosures about Segments of an Enterprise and Related 
Information." The adoption of both standards is required for 
fiscal years beginning after December 15, 1997. Under SFAS 130, 
the Company is required to report comprehensive income in the 
financial statements, in addition to net income. For the Company, 
the primary differences between net income and comprehensive 
income will be from foreign currency translation adjustments and 
net unrealized gains or losses on securities available for sale. 
SFAS 131 requires that the Company report separately, in the 
financial statements, certain financial and descriptive 
information about operating segments. It also establishes 
standards for related disclosures about products and services, 
geographic areas and major customers. Adoption of SFAS 130 and 131 
will not impact the Company's consolidated financial position, 
results of operations or cash flows.

Year 2000 compliance.  Many older computer software programs refer 
to years in terms of their final two digits only. Such programs 
may interpret the year 2000 to mean the year 1900 instead. If not 
corrected, those programs could cause date-related transaction 
failures. Beginning in fiscal 1997, the Company started a process 
to review its internal systems for year 2000 compliance. Testing 
of the internal systems was substantially completed during fiscal 
1998 and the Company believes its current internal systems are 
compliant. Dionex believes the products it is currently shipping 
are year 2000 compliant as well. The Company has no obligation to 
upgrade previously shipped products which are not year 2000 
compliant but may make available for sale to customers fixes for 
certain products.  Additionally, the Company has contacted 
numerous vendors and customers to assess their progress in 
addressing the year 2000 issue. Based upon our assessments, 
testing and the plans in progress, the Company does not believe 
that the year 2000 issue will have a material adverse effect on 
the Company's financial position, results of operation or cash 
flows. However, the Company does not have control over whether its 
vendors or customers will make any appropriate modifications on a 
timely basis. If such modifications are not made in a timely 
manner, the financial position and results of operations could be 
materially adversely affected.  To date, the Company has not 
incurred any significant costs related to this issue, and does not 
expect significant costs directly related to year 2000 compliance 
issues in the future.  However, should the need arise, the Company 
has adequate resources and would use them to resolve significant 
year 2000 issues in a timely manner.  





19
<PAGE>
Forward-looking statements.  Except for historical information 
contained herein, the above discussion and the letter to 
shareholders contains forward-looking statements within the 
meaning of Section 27A of the Securities Act of 1933, as amended, 
Section 21E of the Securities and Exchange Act of 1934, as 
amended, and the Private Securities Litigation Reform Act of 1995, 
and are made under the safe harbor provisions thereof. Such 
statements are subject to certain risks and uncertainties that 
could cause actual results to differ materially from those 
discussed here. Such risks and uncertainties include: general 
economic conditions, foreign currency fluctuations, new product 
development, including market receptiveness, competition from 
other products, existing product obsolescence, fluctuation in 
worldwide demand for analytical instrumentation, the ability to 
manufacture products on an efficient and timely basis and at a 
reasonable cost and in sufficient volume, year 2000 compliance 
issues, the ability to attract and retain talented employees and 
other risks as described in more detail in the Company's Form 10-
K. Readers are cautioned not to place undue reliance on these 
forward-looking statements which reflect management's analysis 
only as of the date hereof. The Company undertakes no obligation 
to publicly release the results of any revision to these forward-
looking statements which may be made to reflect events or 
circumstances after the date hereof or to reflect the occurrence 
of unanticipated events.

Item 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK.

The Company is exposed to financial market risks, including 
changes in foreign currency exchange rates, interest rates and 
marketable equity security prices.  To mitigate its foreign 
currency exchange risks, the Company utilizes derivative financial 
instruments.  The Company does not use derivative financial 
instruments for speculative or trading purposes.

The Company hedges foreign currency exchange risk on its 
intercompany receivable balances utilizing foreign exchange 
forward contracts with high quality financial institutions.  The 
Company's foreign exchange forward hedging activities do not 
subject the company to significant risk due to exchange rate 
movements because gains and losses on these contract generally 
offset losses and gains on the underlying items being hedged.  A 
10% change in foreign currency exchange rates would not have a 
material impact on the Company's results of operations.

The Company has investments in marketable debt securities that are 
subject to interest rate risk. However, due to the short-term 
nature of the Company's debt investments and the Company's 
intention is to hold these investments until maturity, the impact 
of interest rate changes would not have a material impact on the 
Company's results of operations.




20
<PAGE>
The Company is exposed to equity price risk on its investment in 
Molecular Devices Corporation.  This investment is classified as 
"available for sale" and is included in other noncurrent assets.  
The Company does not attempt to reduce or eliminate its market 
exposure on this investment.  A 10% change in the market price of 
the Company's investment would result in an approximately $600,000 
decrease in the fair value of the Company's "available for sale" 
securities.  Although changes in equity prices may affect the fair 
value of "available for sale" securities and cause unrealized 
gains or losses, such gains or losses would not be realized unless 
the investment was sold.

All of the potential changes noted above are based upon 
sensitivity analyses performed on the Company's financial 
positions at June 30, 1998.  Actual results may differ materially.

Item 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

	     See Index to Financial Statements and Financial
	     Statement Schedules appearing on page 28 of this
	     Form 10-K.

Item 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
		ACCOUNTING AND FINANCIAL DISCLOSURE

		Not Applicable.































21
<PAGE>
PART III

Item 10.  DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

		Identification of Directors

		The information required by Item 10 of Form 10-K with
		respect to identification of directors is incorporated
		by reference to the information contained in the
		section captioned "Nominees" at pages 2 and 3 of the
		Registrant's definitive Proxy Statement for the Annual
		Meeting of Stockholders to be held October 22, 1998,
		which has been previously filed.

		Identification of Officers

		See Page 14 of this Report.

Item 11.  EXECUTIVE COMPENSATION

		The information required by Item 11 of Form 10-K is
		incorporated by reference to the information contained
		in the section captioned "Executive Compensation," at
		pages 6 through 9 of the Registrant's definitive
		Proxy Statement for the Annual Meeting of Stockholders
		to be held October 22, 1998, which has been previously
		filed.

Item 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
	     MANAGEMENT

  The information required by Item 12 of Form 10-K is
		incorporated by reference to the information contained
		in the sections captioned "Security Ownership of 
		Certain Beneficial Owners and Management" at pages 4
		and 5 of the Registrant's definitive Proxy Statement
		for the Annual Meeting of Stockholders to be held
		October 22, 1998, which has been previously filed.

Item 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

	     None.















22
<PAGE>
PART IV

Item 14.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON
          FORM 8-K

  (a)(1) Financial Statements - See Index to Financial
	            Statements and Financial Statement Schedules at
		       page 28 of this Report.  

		   (2) Financial Statement Schedules - See Index to
		       Financial Statements and Financial Statement
         Schedules at page 28 of this Report.

     (3) Exhibits - See Exhibit Index at page 24 through
  26 of this Report. 

          (b) Reports on Form 8-K - The Company did not file any
		    reports on Form 8-K during the quarter ended
		    June 30, 1998.  






































23
<PAGE>
DIONEX CORPORATION 

EXHIBIT INDEX

Exhibit
Number 				       Description				                      Reference

 3.1    Restated Certificate of Incorporation,
          filed November 6, 1996.......................    (8)

 3.2    Bylaws, as amended on March 10, 1998...........    

 4.1    Shareholder Rights Agreement dated June 27, 1989,
          between the Registrant and The First National
        		Bank of Boston ..............................    (4)

 4.2    Amendment No. 1 to the Rights Agreement dated
          November 17, 1995............................    (7)

10.1    Agreement, effective as of January 1, 1975,
          between The Dow Chemical Company and
          International Plasma Corporation.............    (1)

10.2    Memorandum agreement, dated March 14, 1975,
          between The Dow Chemical Company and
          International Plasma Corporation.............    (1)

10.3    Agreement, dated March 6, 1975, between
          International Plasma Corporation and the
          former Dionex Corporation....................    (1)

10.4    Consent to Assignment executed as of March 26,
          1980, between the Dow Chemical Company and the
          former Dionex Corporation....................    (1)
 
10.5    Amendatory Agreement, effective as of November 1,
          1981,between The Dow Chemical Company and the
          Registrant (with certain confidential information
          deleted)........................................ (1)

10.6    Amendatory Agreement, effective as of July 1, 1982,
          between The Dow Chemical Company and the
          Registrant (with certain confidential information
          deleted)........................................ (1)

10.7    Registrant's Supplemental Stock Option Plan
          (Exhibit 28.4).................................. (2)

10.8    Registrant's Medical Care Reimbursement Plan
          (Exhibit 10.17)...............................   (1)

10.9    Registrant's Employee Stock Participation Plan
          (Exhibit 28.3)................................   (5)

					  	


24
<PAGE>
Exhibit
Number 				Description		     	Reference

10.10   Credit Agreement dated February 26, 1996
          between Bank of America and the Registrant      (7)

10.11   First amendment to Credit Agreement dated
          February 29, 1996 between Bank of America
          and the Registrant..........................

10.12   Second amendment to Credit Agreement dated
          February 29, 1996 between Bank of America
          and the Registrant..........................

10.13   1988 Directors' Stock Option Plan (and related
         stock option grant form) (Exhibit 10.20).....    (3)

10.14   Dionex Corporation Stock Option Plan, as
        amended and restated (formerly, the 1990 Stock
        Option Plan)..................................    (6)

13.1    Portions of the Registrant's 1998 Annual
           Report to Stockholders that are incorporated
           by reference in this Annual Report on
           Form 10-K.................................

 21.1    Subsidiaries of Registrant..................

 23.1    Independent Auditors' Consent...............


 27.1    Financial Data Schedule.....................


(1)	Incorporated by reference to the indicated exhibit in
     Amendment No. 1 of the Registrant's Registration
     Statement on Form S-1 filed December 7, 1982.

(2)	Incorporated by reference to the indicated exhibit in the
     Registrant's Registration Statement on Form S-8 filed
     March 3, 1987.

(3)	Incorporated by reference to the indicated exhibit in the
     Registrant's Annual Report on Form 10-K filed September
     27, 1988. 

(4)	Incorporated by reference to the corresponding exhibit in
     the Registrant's Current Report on Form 8-K filed June 29,
     1989.








25
<PAGE>
(5)	Incorporated by reference to the indicated exhibit in the
     Registrant's Statement on Form S-8 filed May 6, 1994. 

(6)	Incorporated by reference to the indicated exhibit in the
     Registrant's Annual Report on Form 10-K filed September 26,
     1995.

(7)  Incorporated by reference to the indicated exhibit in the
     Registrant's Annual Report on Form 10-K filed September 26,
	    1996.  

(8)	Incorporated by reference to the indicated exhibit in the
     Registrant's Quarterly Report on Form 10-Q filed February 13,
     1997.











































26
<PAGE>
SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the 
Securities Exchange Act of 1934, the Registrant has duly caused 
this report to be signed on its behalf by the undersigned, 
thereunto duly authorized.


               DIONEX CORPORATION
		               	(Registrant)

Date September 25, 1998  	By /s/ A. Blaine Bowman
                                 A. Blaine Bowman
                                 President and Chief Executive
                        						   Officer

Pursuant to the requirements of the Securities Exchange Act of 
1934, this report has been signed below by the following persons 
on behalf of the Registrant and in the capacities and on the dates 
indicated.


   Signature                   Title                        Date


/s/ A. Blaine Bowman    President,Chief Executive    September 25, 1998
A. Blaine Bowman        Officer, and Director
	           		         (Principal Executive Officer)

/s/ Michael W. Pope     Vice President of Finance    September 25, 1998
Michael W. Pope	        and Administration
				                   (Principal Financial and
				                    Accounting Officer)

/s/ David L. Anderson   Director	          		        September 25, 1998
David L. Anderson


/s/ James F. Battey	    Director			                  September 25, 1998
James F. Battey


/s/ B.J. Moore		        Director 		         	        September 25, 1998
B.J. Moore

/s/ Riccardo Pigliucci  Director 		         	        September 25, 1998
Riccardo Pigliucci










27
<PAGE>
DIONEX CORPORATION

INDEX TO FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES


        		                                                Page

FINANCIAL STATEMENTS

Consolidated Balance Sheets at June 30, 1998 and 1997      *

Consolidated Statements of Income for the years
  ended June 30, 1998, 1997 and 1996				                   *

Consolidated Statements of Stockholders' Equity for
  the years ended June 30, 1998, 1997 and 1996             *

Consolidated Statements of Cash Flows for the years
  ended June 30, 1998, 1997 and 1996			               	    *

Notes to Consolidated Financial Statements			              *

Independent Auditors' Report				                     		    *

*Incorporated by reference to information contained on
 pages 25 through 39 of the Registrant's 1998 Annual
 Report to Stockholders. A copy of the applicable pages
 is attached hereto as Exhibit 13.1  




FINANCIAL STATEMENT SCHEDULES

Independent Auditors' Report				                    		   29

Schedule II - Valuation and Qualifying Accounts
 and Reserves		                                          30


All other schedules are omitted because they are not required, are 
not applicable or the information is included in the consolidated 
financial statements or notes thereto.













28
<PAGE>
INDEPENDENT AUDITORS' REPORT

Dionex Corporation

We have audited the consolidated financial statements of Dionex 
Corporation and its subsidiaries as of June 30, 1998 and 1997, and 
for each of the three years in the period ended June 30, 1998, and 
have issued our report thereon dated July 20, 1998; such financial 
statements and report are included in your 1998 Annual Report to 
Stockholders and are included in and incorporated by reference 
herein.  Our audits also included the consolidated financial 
statement schedule of Dionex Corporation and its subsidiaries, 
listed in the accompanying Index to Financial Statements and 
Financial Statement Schedules.  This financial statement schedule 
is the responsibility of the Company's management.  Our 
responsibility is to express an opinion based on our audits.  In 
our opinion, such financial statement schedule, when considered in 
relation to the basic consolidated financial statements taken as a 
whole, presents fairly in all material respects the information 
set forth therein.






DELOITTE & TOUCHE LLP

San Jose, California
July 20, 1998



























29
<PAGE>